NSE: AHCL · BSE: 544497
ANLON HEALTHCARE LIMITED
Manufactures and sells pharmaceutical active ingredients, with a focus on pain management APIs. Runs contract development and manufacturing projects for global innovator drug companies, with 3 molecules currently under development for 2 such companies, and has filed 21 Drug Master Files to date. In Q1 FY27, acquired a 63.98% stake in Remember India Health Links to enter finished dosage formulations, bringing in 30+ formulation dossiers, and incorporated two new subsidiaries to build a presence in peptides/biosimilars and surgical implants/medical devices. Sells to pharmaceutical, nutraceutical, veterinary and personal care customers across 15+ countries and has begun diversifying into industrial and fine chemicals. Raw materials form the bulk of operating costs, with depreciation and employee costs making up smaller shares. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Active Pharmaceutical Ingredients (APIs), CDMO services, Finished Dosage Formulations, Industrial & Fine Chemicals. Pharmaceutical API manufacturer and CDMO player diversifying into formulations, biologics and medical devices.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 172 |
| EBITDA (ex other income) | 48 |
| margin % | 27.6 |
| Owners' profit | 29 |
| EPS, as reported (₹) | 6.11 |
| ROE % · ROCE % | 11.4 · 17.4 |
| Debt / equity (x) | 0.17 |
| Cash from operations | (79) |
| Capex | 0 |
Exhibit 2: Quarterly performance, last 2 quarters
| ₹ crore | Q4 FY26 | Q1 FY27 |
|---|---|---|
| Revenue | 51 | 88 |
| Profit before tax | 14 | 14 |
| Net profit | 11 | 8 |
| EPS (₹) | 2.33 | 0.16 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 9.8 | 30.1 | 18 of 158 | 89% |
| P/B | 5.1 | 3.0 | 118 of 163 | 28% |
| ROCE | 16.0 | 10.8 | 54 of 183 | 71% |
| ROE | 11.4 | 9.8 | 73 of 166 | 56% |
| Debt / Equity | 0.2 | 0.2 | 88 of 166 | 47% |
| EBITDA margin | 17.9 | 17.5 | 80 of 165 | 52% |
| Market cap | 1295 | 810 | 85 of 181 | 53% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Anlon Healthcare schedules Q2 and H1 FY27 earnings call | board shareholder meetings | low | — | — |
| 24 Oct 2026 · Board meeting set to approve Q2 and half-year results | results | low | — | — |
| 19 Oct 2026 · SDD Compliance Certificate for Quarter ended September 30, 2026 | compliance | minimal | — | — |
| 19 Oct 2026 · Routine SEBI compliance certificate for Q2 FY26 filed with exchanges | compliance | minimal | — | — |
| 13 Oct 2026 · Board approves up to Rs 250 crore preferential issue of convertible warrants | fund raising | high | — | — |
| 29 Sept 2026 · Board meet on Oct 13 to discuss expansion and fundraise plans | capex operations | medium | — | — |
| 28 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 FY27 results | compliance | minimal | — | — |
| 24 Sept 2026 · Anlon Healthcare to participate in Arihant Capital Rising Stars 2026 conference | general | low | — | — |
| 21 Sept 2026 · Incorporates Nigeria subsidiary to expand into West African pharma market | strategic transactions | medium | — | — |
| 21 Sept 2026 · Anlon Healthcare share swap for acquisitions approved by shareholders | strategic transactions | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.